<p>Fayez Sarofim
&amp; Co 在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在雅培（NYSE:ABT - 免費報告）股票的持有量降低了 2.2%。該基金在季度內出售了 99,447 股後，持有 4,522,297 股這家醫療產品製造商的股票。雅培在 Fayez Sarofim
&amp; Co 的投資組合中佔約 1.5%，使其成為該基金的第 22 大持倉。截至最近的 SEC 文件，Fayez Sarofim
&amp; Co 持有的雅培股份約佔 0.26%，價值 619,107,000 美元。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超預期後的新底部</li>
</ul>
<p>其他幾家對沖基金最近也對其在該公司的持倉進行了調整。IMG Wealth Management Inc. 在第二季度將其在雅培的持倉增加了 759.1%。IMG Wealth Management Inc. 現在持有 189 股這家醫療產品製造商的股票，價值 26,000 美元，此前在上個季度又增持了 167 股。Elequin Capital LP 在第一季度購買了雅培的新股份，價值約 30,000 美元。Anfield Capital Management LLC 在第二季度將其在雅培的持倉增加了 81.3%。Anfield Capital Management LLC 現在持有 232 股這家醫療產品製造商的股票，價值 32,000 美元，此前在此期間又購買了 104 股。Curio Wealth LLC 在第二季度將其在雅培的持倉增加了 15,250.0%。Curio Wealth LLC 現在持有 307 股這家醫療產品製造商的股票，價值 42,000 美元，此前在上個季度又購買了 305 股。最後，Pineridge Advisors LLC 在第二季度將其在雅培的持倉增加了 34.6%。Pineridge Advisors LLC 現在持有 315 股這家醫療產品製造商的股票，價值 43,000 美元，此前在此期間又購買了 81 股。目前，75.18% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>雅培股票表現</h2>
<p>週二，ABT 股票開盤價為 121.88 美元。該公司的市值為 2119.3 億美元，市盈率為 15.27，PEG 比率為 2.28，貝塔值為 0.71。雅培的 52 周低點為 110.86 美元，52 周高點為 141.23 美元。該公司的速動比率為 1.24，流動比率為 1.70，債務股本比率為 0.23。公司的 50 日移動平均線為 128.31 美元，200 日移動平均線為 130.72 美元。</p>
<ul>
<li>雅培十月股價暴跌是買入信號</li>
</ul>
<p>雅培（NYSE:ABT - 獲取免費報告）最近於 10 月 15 日（星期三）公佈了其財報。這家醫療產品製造商報告本季度每股收益（EPS）為 1.30 美元，符合市場共識預期的 1.30 美元。雅培的股本回報率為 17.60%，淨利潤率為 31.88%。該公司的季度收入為 113.7 億美元，而分析師預期為 114 億美元。去年同期，該公司每股收益為 1.21 美元。該公司的季度收入同比增長 6.9%。雅培已將其 2025 財年的指導目標設定為每股收益 5.120-5.180 美元。平均而言，賣方分析師預計雅培在當前財年將發佈每股收益 5.14 美元。</p>
<h2>雅培股息公告</h2>
<p>該公司最近還宣佈了季度股息，已於 11 月 17 日（星期一）支付。10 月 15 日（星期三）登記在冊的股東獲得了 0.59 美元的股息。除息日期為 10 月 15 日（星期三）。這代表着年化股息為 2.36 美元，收益率為 1.9%。雅培的派息比率目前為 29.57%。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>為什麼雅培在 2025 年第二季度是一個買入機會：增長與收益</li>
</ul>
<p>多家研究分析師對該股票發表了看法。Raymond James Financial 將雅培股票的目標價從 141.00 美元上調至 146.00 美元，並在 10 月 16 日的研究報告中給予該公司 “跑贏大盤” 的評級。大和資本市場將雅培股票的目標價從 134.00 美元上調至 136.00 美元，並在 10 月 21 日的報告中給予該公司 “跑贏大盤” 的評級。Evercore ISI 將雅培股票的目標價從 144.00 美元下調至 142.00 美元，並在 10 月 15 日的研究報告中對該股票給予 “跑贏大盤” 的評級。William Blair 在 11 月 20 日的研究報告中將雅培升級為 “強力買入” 評級。最後，富國銀行將雅培的目標價從 142.00 美元上調至 146.00 美元，並在 10 月 16 日的報告中給予該股票 “增持” 的評級。兩位研究分析師對該股票給予 “強力買入” 評級，十七位給予 “買入” 評級，四位給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標價為 147.00 美元。</p>
<p><strong>查看我們最新的雅培股票報告</strong></p>
<h2>雅培公司簡介</h2>
<p>（免費報告）</p>
<p>雅培及其子公司在全球範圍內發現、開發、製造和銷售醫療產品。它分為四個部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不全、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭性眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>如何投資藍籌股</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的啓示</li>
<li>什麼是特別股息？</li>
<li>2026 年最有可能拆分的三隻股票</li>
<li>如何投資小盤股</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次充滿活力</li>
</ul>
<p><strong>想看看其他對雅培持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
<p>在你考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而雅培並不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

雅培

<p>Fayez Sarofim & Co 在第二季度減少了對雅培的持股，減持幅度為 2.2%，出售了 99,447 股。雅培的股票開盤價為 121.88 美元，市值為 2119.3 億美元。分析師預測公司將實現增長，目標股價範圍在 134 美元到 146 美元之間。雅培第三季度的收益符合預期，公司宣佈每股季度分紅為 0.59 美元。由於增長和收益潛力，該股票被認為在 2025 年第二季度值得買入</p>

<p>Fayez Sarofim &amp; Co lowered its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 2.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 4,522,297 shares of the healthcare product maker's stock after selling 99,447 shares during the quarter. Abbott Laboratories accounts for about 1.5% of Fayez Sarofim &amp; Co's portfolio, making the stock its 22nd largest position. Fayez Sarofim &amp; Co owned about 0.26% of Abbott Laboratories worth $619,107,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Fayez Sarofim
&amp; Co 在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在雅培（NYSE:ABT - 免費報告）股票的持有量降低了 2.2%。該基金在季度內出售了 99,447 股後，持有 4,522,297 股這家醫療產品製造商的股票。雅培在 Fayez Sarofim
&amp; Co 的投資組合中佔約 1.5%，使其成為該基金的第 22 大持倉。截至最近的 SEC 文件，Fayez Sarofim
&amp; Co 持有的雅培股份約佔 0.26%，價值 619,107,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超預期後的新底部</li>
</ul>
</div><p>Several other hedge funds have also recently made changes to their positions in the business. IMG Wealth Management Inc. grew its position in Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock worth $26,000 after acquiring an additional 167 shares in the last quarter. Elequin Capital LP bought a new stake in shares of Abbott Laboratories in the 1st quarter valued at approximately $30,000. Anfield Capital Management LLC boosted its holdings in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock worth $32,000 after purchasing an additional 104 shares during the period. Curio Wealth LLC increased its position in shares of Abbott Laboratories by 15,250.0% during the 2nd quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock valued at $42,000 after purchasing an additional 305 shares during the last quarter. Finally, Pineridge Advisors LLC raised its holdings in Abbott Laboratories by 34.6% during the 2nd quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker's stock valued at $43,000 after buying an additional 81 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也對其在該公司的持倉進行了調整。IMG Wealth Management Inc. 在第二季度將其在雅培的持倉增加了 759.1%。IMG Wealth Management Inc. 現在持有 189 股這家醫療產品製造商的股票，價值 26,000 美元，此前在上個季度又增持了 167 股。Elequin Capital LP 在第一季度購買了雅培的新股份，價值約 30,000 美元。Anfield Capital Management LLC 在第二季度將其在雅培的持倉增加了 81.3%。Anfield Capital Management LLC 現在持有 232 股這家醫療產品製造商的股票，價值 32,000 美元，此前在此期間又購買了 104 股。Curio Wealth LLC 在第二季度將其在雅培的持倉增加了 15,250.0%。Curio Wealth LLC 現在持有 307 股這家醫療產品製造商的股票，價值 42,000 美元，此前在上個季度又購買了 305 股。最後，Pineridge Advisors LLC 在第二季度將其在雅培的持倉增加了 34.6%。Pineridge Advisors LLC 現在持有 315 股這家醫療產品製造商的股票，價值 43,000 美元，此前在此期間又購買了 81 股。目前，75.18% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表現</h2>
</div><p>Shares of ABT stock opened at $121.88 on Tuesday. The firm has a market cap of $211.93 billion, a price-to-earnings ratio of 15.27, a PEG ratio of 2.28 and a beta of 0.71. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The company's 50 day moving average is $128.31 and its 200 day moving average is $130.72.</p>
<div class="lb-trans"><p>週二，ABT 股票開盤價為 121.88 美元。該公司的市值為 2119.3 億美元，市盈率為 15.27，PEG 比率為 2.28，貝塔值為 0.71。雅培的 52 周低點為 110.86 美元，52 周高點為 141.23 美元。該公司的速動比率為 1.24，流動比率為 1.70，債務股本比率為 0.23。公司的 50 日移動平均線為 128.31 美元，200 日移動平均線為 130.72 美元。</p>
</div><ul>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培十月股價暴跌是買入信號</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The business had revenue of $11.37 billion for the quarter, compared to analysts' expectations of $11.40 billion. During the same quarter last year, the firm earned $1.21 EPS. The business's revenue for the quarter was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近於 10 月 15 日（星期三）公佈了其財報。這家醫療產品製造商報告本季度每股收益（EPS）為 1.30 美元，符合市場共識預期的 1.30 美元。雅培的股本回報率為 17.60%，淨利潤率為 31.88%。該公司的季度收入為 113.7 億美元，而分析師預期為 114 億美元。去年同期，該公司每股收益為 1.21 美元。該公司的季度收入同比增長 6.9%。雅培已將其 2025 財年的指導目標設定為每股收益 5.120-5.180 美元。平均而言，賣方分析師預計雅培在當前財年將發佈每股收益 5.14 美元。</p>
</div><h2>Abbott Laboratories Dividend Announcement</h2>
<div class="lb-trans"><h2>雅培股息公告</h2>
</div><p>The company also recently announced a quarterly dividend, which was paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th were issued a $0.59 dividend. The ex-dividend date was Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.9%. Abbott Laboratories's payout ratio is currently 29.57%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度股息，已於 11 月 17 日（星期一）支付。10 月 15 日（星期三）登記在冊的股東獲得了 0.59 美元的股息。除息日期為 10 月 15 日（星期三）。這代表着年化股息為 2.36 美元，收益率為 1.9%。雅培的派息比率目前為 29.57%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼雅培在 2025 年第二季度是一個買入機會：增長與收益</li>
</ul>
</div><p>A number of research analysts have weighed in on the stock. Raymond James Financial boosted their price objective on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, October 16th. Daiwa Capital Markets upped their price target on shares of Abbott Laboratories from $134.00 to $136.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, October 21st. Evercore ISI reduced their price objective on shares of Abbott Laboratories from $144.00 to $142.00 and set an &#34;outperform&#34; rating on the stock in a research report on Wednesday, October 15th. William Blair upgraded Abbott Laboratories to a &#34;strong-buy&#34; rating in a research report on Thursday, November 20th. Finally, Wells Fargo &amp; Company increased their price target on Abbott Laboratories from $142.00 to $146.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $147.00.</p>
<div class="lb-trans"><p>多家研究分析師對該股票發表了看法。Raymond James Financial 將雅培股票的目標價從 141.00 美元上調至 146.00 美元，並在 10 月 16 日的研究報告中給予該公司 “跑贏大盤” 的評級。大和資本市場將雅培股票的目標價從 134.00 美元上調至 136.00 美元，並在 10 月 21 日的報告中給予該公司 “跑贏大盤” 的評級。Evercore ISI 將雅培股票的目標價從 144.00 美元下調至 142.00 美元，並在 10 月 15 日的研究報告中對該股票給予 “跑贏大盤” 的評級。William Blair 在 11 月 20 日的研究報告中將雅培升級為 “強力買入” 評級。最後，富國銀行將雅培的目標價從 142.00 美元上調至 146.00 美元，並在 10 月 16 日的報告中給予該股票 “增持” 的評級。兩位研究分析師對該股票給予 “強力買入” 評級，十七位給予 “買入” 評級，四位給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標價為 147.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的雅培股票報告</strong></p>
</div><h2>Abbott Laboratories Company Profile</h2>
<div class="lb-trans"><h2>雅培公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培及其子公司在全球範圍內發現、開發、製造和銷售醫療產品。它分為四個部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不全、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭性眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>What is a Special Dividend?</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>How to Invest in Small Cap Stocks</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>如何投資藍籌股</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的啓示</li>
<li>什麼是特別股息？</li>
<li>2026 年最有可能拆分的三隻股票</li>
<li>如何投資小盤股</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次充滿活力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對雅培持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而雅培並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Fayez Sarofim & Co 出售了 99,447 股雅培公司（Abbott Laboratories）的股票，股票代碼為$ABT